新光药业公告，信息披露义务人嵊州市和丰投资股份有限公司通过集中竞价与大宗交易方式减持公司股 份1070.01万股，占公司总股本的6.6876%，其持股比例从21.6875%下降至14.9999%。本次权益变动触及 1%及5%的整数倍。 ...

证券代码：300519 证券简称：新光药业 公告编号：2026-001 浙江新光药业股份有限公司 关于持股5%以上股东持股比例变动触及5%整数倍 暨披露简式权益变动报告书的提示性公告 持股 5%以上股东嵊州市和丰投资股份有限公司（以下简称"和丰投资"）保 证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次权益变动属于持股 5%以上股东和丰投资实施前期已披露的股份减持 计划。本次权益变动后，和丰投资持有公司股份数量从 34,700,000 股减少至 23,999,900 股，持股比例从 21.6875%下降至 14.9999%，权益变动触及 5%的整 数倍。 2、本次权益变动主体和丰投资不属于公司第一大股东、控股股东及实际控 制人，本次权益变动不会导致公司第一大股东、控股股东及实际控制人发生变 化，不会对公司治理结构及持续经营产生重大影响。 3、本次权益变动性质为股份减少，不触及要约收购。 浙江新光药业股份有限公司（以下简称"公司"）于 2022 年 1 月 4 日在巨潮 资讯网上披露了《关于 ...

浙江新光药业股份有限公司 简式权益变动报告书 上市公司名称：浙江新光药业股份有限公司 股票上市地点：深圳证券交易所 股票简称：新光药业 股票代码：300519 信息披露义务人：嵊州市和丰投资股份有限公司 住所/通讯地址：浙江省嵊州市剡湖街道江滨西路 585 号 股份变动性质：股份数量减少，持股比例下降至 15%以下 签署日期：2026 年 2 月 6 日 1 信息披露义务人声明 一、本报告书系依据《中华人民共和国证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》 及相关的法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露信息披露义务人在浙江新光药业股份有限公司中拥有权益的 股份变动情况。截至本报告书签署之日，除本报告书披露的信息外，信息披露义 务人没有通过任何其他方式增加或减少其在新光药业中拥有权益的股份。 四、本次权益变动是根据本报告所载明的资料进行的。信息披露义务人没有 委托或者授权其它任何人提供未在本报告书列载的信息和对本报告书 ...

Group 1 - The core point of the article highlights that New Light Pharmaceutical's stock rose by 2.89% to close at 15.33 yuan, with a significant block trade occurring [1] - The block trade involved a total volume of 210,000 shares and a transaction amount of 2.5032 million yuan, with the first transaction price at 11.92 yuan, reflecting a premium rate of -22.24% [1] - The buyer and seller of the block trade were both from Guotai Junan Securities Co., Ltd., specifically the Shengzhou Gaoyang Road Securities Business Department [1] Group 2 - Over the past three months, the stock has recorded a total of one block trade with a cumulative transaction amount of 2.5032 million yuan [1] - In the last five trading days, the stock has experienced a cumulative decline of 0.52%, with a net outflow of main funds amounting to 7.3349 million yuan [1]

Summary of Key Points Core Viewpoint - On January 5, 2026, Xinguang Pharmaceutical conducted a block trade of 210,000 shares at a transaction price of 11.92 yuan, which represents a discount of 22.24% compared to the market closing price of 15.33 yuan [1]. Group 1: Transaction Details - The total transaction amount for the block trade was 250.32 thousand yuan, accounting for 4.41% of the total trading volume on that day [1]. - The buyer and seller for this transaction were both from Guotai Junan Securities Co., Ltd., specifically from the Shengzhou Gaoyang Road Securities Business Department [2].

Core Viewpoint - Xinguang Pharmaceutical (300519) has announced that its new drug "YHTKL" has completed the basic research of prescriptions and is now entering the stage of process and quality standard research [1] Group 1 - The company has responded to investor inquiries on its interactive platform regarding the progress of its new drug [1] - The new drug "YHTKL" is currently in the process of developing its quality standards [1]

Market Overview - The traditional Chinese medicine sector experienced a decline of 0.28% on December 8, with Weikang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Xinguang Pharmaceutical (300519) with a closing price of 17.34, up 3.96% and a trading volume of 131,800 shares, totaling 229 million yuan [1] - Kanghui Co., Ltd. (603139) closed at 22.35, up 2.48% with a trading volume of 20,300 shares, totaling 45.04 million yuan [1] - Conversely, Weikang Pharmaceutical (300878) saw a significant decline of 8.00%, closing at 22.66 with a trading volume of 110,800 shares, totaling 251 million yuan [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 723 million yuan from institutional investors, while retail investors saw a net inflow of 469 million yuan [2] - The capital flow for specific stocks showed: - Yunnan Baiyao (000538) had a net inflow of 26.56 million yuan from institutional investors, while retail investors had a net outflow of 6,450 yuan [3] - Kang Enbei (600572) reported a net inflow of 21.85 million yuan from institutional investors, with a net outflow of 1.92 million yuan from retail investors [3]

Core Viewpoint - The A-share market showed a decline with the Shanghai Composite Index closing at 3878.00 points, down 0.51% and below the five-day moving average, with a total trading volume of 168.36 billion yuan [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3878.00 points, reflecting a decrease of 0.51% [1]. - The total trading volume in the A-share market reached 168.36 billion yuan [1]. Group 2: Stocks Breaking the Five-Day Moving Average - A total of 233 A-shares broke above the five-day moving average today [1]. - Notable stocks with significant deviation rates include: - Sifangda (300179) with a deviation rate of 12.01% and a daily increase of 15.37% [1]. - *ST Changyao (300391) with a deviation rate of 11.26% and a daily increase of 20.09% [1]. - Jindike (688670) with a deviation rate of 8.49% and a daily increase of 15.93% [1]. Group 3: Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that just crossed the five-day moving average include: - Jiuli Special Materials (300996) with a deviation rate of 8.38% and a daily increase of 11.38% [1]. - Zhongheng Design (603017) with a deviation rate of 8.14% and a daily increase of 9.98% [1]. - Shuangqiang Technology (001211) with a deviation rate of 7.13% and a daily increase of 9.99% [1].

Group 1 - The core viewpoint of the articles highlights the active performance of flu-related stocks in the A-share market, driven by a rising trend in acute respiratory infectious diseases in China, particularly influenza [1][2] - The National Influenza Center reported that 17 provinces in China have reached high flu levels, with expectations of peak activity in mid-December [1] - The dominant circulating strain is the H3N2 subtype, accounting for over 95% of cases, with some H1N1 and B strains also present [1] Group 2 - Recent data indicates a significant increase in orders for antiviral medications, with orders for flu-specific drugs rising nearly ninefold compared to October, particularly for Maviroc and Oseltamivir [2] - Various pharmaceutical companies have shown notable stock price increases, with Guangdong Wannianqing rising over 11% and other companies like Yisheng Pharmaceutical and Jindike also experiencing substantial gains [3] - The overall supply of flu-related medications is reported to be sufficient, with recommendations for consumers to avoid panic buying [2]

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]